Demyelinating and Neurologic Events Reported in Association with Tumor Necrosis Factor α Antagonism: By What Mechanisms Could Tumor Necrosis Factor a Antagonists Improve Rheumatoid Arthritis but Exacerbate Multiple Sclerosis?

Arthritis and Rheumatism

Volumn 44, Issue 9, 2001, Pages 1977-1983

  Robinson, William H ^a   Genovese, Mark C ^a   Moreland, Larry W ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; MULTIPLE SCLEROSIS; REVIEW; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; MULTIPLE SCLEROSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035464263     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6     Document Type: Review

References (40)

1. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
2. Elliott M, Maini RN, Feldman M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
3. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Siegel JN. Demyelination diagnosed during etanercept (TNF receptor fusion protein) therapy [abstract]. Arthritis Rheum 2000;43 Suppl 9:S228.
4. Wyeth-Ayerst Laboratories and Immunex Inc. [Revised package insert for etanercept.] 2000.
5. Van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BME, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-4.
6. Johnson and Johnson, Inc. [Revised package insert for infliximab.] 2001.
7. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-65.
8. Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997;84: 223-43.
9. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52.
10. Cope A, Ettinger R, McDevitt H. The role of TNFα and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol 1997;148:307-12.
11. Klareskog L, McDevitt H. Rheumatoid arthritis and its animal models: the role of TNF-α and the possible absence of specific immune reactions. Curr Opin Immunol 1999;11:657-62.
12. Green EA, Flavell R. Tumor necrosis factor-α and the progression of diabetes in non-obese diabetic mice. Immunol Rev 1999;169: 11-2.
13. Theofilopoulos AN, Lawson BR. Tumor necrosis factor and other cytokines in murine lupus. Ann Rheum Dis 1999;58 Suppl 1:149-55.
14. Kollias G, Douni E, Kassiotis G, Kontoyiannis D. The function of tumor necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Ann Rheum Dis 1999;58 Suppl 1:I32-9.
15. Lock C, Oksenberg J, Steinman L. The role of TNFα and lymphotoxin in demyelinating disease. Ann Rheum Dis 1999;58 Suppl 1:I121-8.
16. Targan SR, Hanauer SR, van Deventer SJH, Mayer L, Present D, Praakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997;337:1029-35.
17. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;23:339-46.
18. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-72.
19. Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991;87:949-54.
20. Bitsch A, Kuhlmann T, da Costa C, Bunkowski S, Polak T, Bruck W. Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology. Glia 2000;29:366-75.
21. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424-35.
22. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999;10:387-98.
23. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci U S A 1995;92:11294-8.
24. Kassiotis G, Bauer J, Akassoglou K, Lassmann H, Kollias G, Probert L. A tumor necrosis factor-induced model of human primary demyelinating diseases develops in immunodeficient mice. Eur J Immunol 1999;29:912-7.
25. Salazar AM, Gibbs CJ, Gajudsek DC, Smith RA. Clinical use of interferons: central nervous system disorders. In: Came P, Carter WA, editors. Handbook of experimental pharmacology. Vol. 71. New York: Springer-Verlag; 1984. p. 471-97.
26. Jacobs L, Salazar AM, Herndon R, Reese PA, Freeman A, Jozefowicz R, et al. Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis: results of a multicenter, double-blinded study. Arch Neurol 1987; 44:589-95.
27. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987;1:893-5.
28. Simon LS, Strand V. Clinical response to nonsteroidal antiinflammatory drugs [editorial]. Arthritis Rheum 1997;40:1940-3.
29. Choy EHS, Connolly DJA, Rapson N, Jeal S, Brown JCC, Kingsley GH, et al. Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (Oxford) 2000;39:1139-46.
30. Ulfgren A-K, Andersson U, Engström M, Klareskog L, Maini RN, Taylor PC. Systemic anti-tumor necrosis factor α therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor α synthesis. Arthritis Rheum 2000;43:2391-6.
31. Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997;185: 1573-84.
32. Khoury SJ, Sayegh MH, Hancock WW, Gallon L, Carpenter CB, Weiner HL. Acquired tolerance to experimental autoimmune encephalomyelitis by intrathymic injection of myelin basic protein or its major encephalitogenic peptide. J Exp Med 1993;178: 559-66.
33. Brabb T, von Dassow P, Ordonz N, Schnabel B, Duke B, Goverman J. In situ tolerance within the central nervous system as a mechanism for preventing autoimmunity. J Exp Med 2000;192: 871-80.
34. Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994; 24:2040-8.
35. Selmaj K, Papierz W, Glabinski A, Kohno T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol 1995;56:135-41.
36. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990;172:1193-200.
37. Selmaj K, Raine CS, Cross AH. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991;30: 694-700.
38. Greenlee JE, Burns JB, Rose JW, Jaeckle KA, Clawson S. Uptake of systemically administered human anticerebellar antibody by rat Purkinje cells following blood-brain barrier disruption. Acta Neuropathol (Berl) 1995;89:341-5.
39. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998;4:78-83.
40. Diehl AM. Cytokine regulation of liver injury and repair. Immunol Rev 2000;174:160-71.